Press coverage about AveXis (NASDAQ:AVXS) has trended somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. AveXis earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.9299976463379 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

A number of brokerages have commented on AVXS. William Blair reiterated a “buy” rating on shares of AveXis in a research report on Tuesday, January 30th. Mizuho began coverage on AveXis in a research report on Monday. They issued a “buy” rating and a $147.00 price objective for the company. Royal Bank of Canada reiterated a “hold” rating and issued a $92.00 price objective on shares of AveXis in a research report on Tuesday, January 9th. BMO Capital Markets reissued a “buy” rating on shares of AveXis in a report on Monday, January 8th. Finally, Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $116.95.

Shares of AveXis (AVXS) traded up $2.36 on Tuesday, hitting $114.26. The stock had a trading volume of 284,664 shares, compared to its average volume of 670,806. AveXis has a fifty-two week low of $53.94 and a fifty-two week high of $128.00. The firm has a market cap of $4,100.00 and a PE ratio of -20.48.

In related news, VP Andrew F. Knudten sold 2,000 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $94.48, for a total transaction of $188,960.00. Following the completion of the sale, the vice president now directly owns 7,000 shares of the company’s stock, valued at approximately $661,360. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $94.77, for a total value of $168,690.60. Following the sale, the vice president now directly owns 1,780 shares of the company’s stock, valued at $168,690.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 57,560 shares of company stock valued at $6,160,062. 18.60% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “AveXis (AVXS) Given Daily Media Impact Score of 0.18” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/02/14/avexis-avxs-given-daily-media-impact-score-of-0-18.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Insider Buying and Selling by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.